However, the plethora of associations of increased ARID3a expression with disease activity in multiple cell types provides strong circumstantial evidence that ARID3a has a major role in SLE pathogenesis, and that ARID3a inhibition may have significant therapeutic benefits in this difficult to treat disease. The gene discussed is ARID3A; the disease is systemic lupus erythematosus.